Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: fingolimod

« Back to Dashboard

Summary for Generic Name: fingolimod

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list16
Suppliers: see list1

Pharmacology for Ingredient: fingolimod

Clinical Trials for: fingolimod

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Status: Terminated Condition: Relapsing Remitting Multiple Sclerosis (RRMS)

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
Status: Recruiting Condition: Multiple Sclerosis-Relapsing-Remitting

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Safety and Efficacy of Fingolimod in MS Patients in China
Status: Withdrawn Condition: Multiple Sclerosis (Relapsing Remitting)

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status: Completed Condition: Multiple Sclerosis

Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
Status: Completed Condition: Acute Demylelinating Optic Neuritis

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
Status: Recruiting Condition: Rett's Syndrome

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Status: Recruiting Condition: Amyotrophic Lateral Sclerosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes<disabled><disabled>
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes5,604,229<disabled>Y<disabled>
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes6,004,565<disabled><disabled>
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes<disabled><disabled>
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527Sep 21, 2010RXYes8,324,283<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc